Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy and COVID-19 Outcomes in Patients With Cancer.
Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, Avutu V, Murciano-Goroff YR, Chan JE, Derkach A, Philip J, Belenkaya R, Kerpelev M, Maloy M, Watson A, Fong C, Janjigian Y, Diaz LA Jr, Bolton KL, Pessin MS. Jee J, et al. Among authors: wills b. J Clin Oncol. 2020 Oct 20;38(30):3538-3546. doi: 10.1200/JCO.20.01307. Epub 2020 Aug 14. J Clin Oncol. 2020. PMID: 32795225 Free PMC article.
Oncologic immunomodulatory agents in patients with cancer and COVID-19.
Jee J, Stonestrom AJ, Devlin S, Nguyentran T, Wills B, Narendra V, Foote MB, Lumish M, Vardhana SA, Pastores SM, Korde N, Patel D, Horwitz S, Scordo M, Daniyan AF. Jee J, et al. Among authors: wills b. Sci Rep. 2021 Mar 1;11(1):4814. doi: 10.1038/s41598-021-84137-5. Sci Rep. 2021. PMID: 33649382 Free PMC article.
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Abu-Sbeih H, et al. Among authors: wills b. J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4. J Clin Oncol. 2019. PMID: 31163011 Free PMC article.
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Balaji A, et al. Among authors: wills b. J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6. J Oncol Pract. 2019. PMID: 31386608 Free PMC article.
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP. Cardona AF, et al. Among authors: wills b. PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016. PLoS One. 2016. PMID: 27191954 Free PMC article.
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Ruiz-Patiño A, et al. Among authors: wills b. Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x. Target Oncol. 2018. PMID: 30284706
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, Archila P, Rodríguez J, Cuello M, Ortíz C, Franco S, Rolfo C, Rosell R, on behalf of the CLICaP. Cardona AF, et al. Among authors: wills b. Oncotarget. 2016 Sep 19;7(42):68933-68942. doi: 10.18632/oncotarget.12112. Oncotarget. 2016. PMID: 27926478 Free PMC article.
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Wills B, et al. Anticancer Res. 2017 Nov;37(11):6429-6436. doi: 10.21873/anticanres.12097. Anticancer Res. 2017. PMID: 29061829
344 results